Cerulean Pharma (NASDAQ: DARE) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Cerulean Pharma to related companies based on the strength of its dividends, valuation, institutional ownership, risk, earnings, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Cerulean Pharma and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cerulean Pharma 0 0 0 0 N/A
Cerulean Pharma Competitors 882 3256 11745 235 2.70

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.73%. Given Cerulean Pharma’s competitors higher probable upside, analysts clearly believe Cerulean Pharma has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Cerulean Pharma and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cerulean Pharma $760,000.00 -$39.30 million -1.11
Cerulean Pharma Competitors $284.49 million $34.10 million 72.85

Cerulean Pharma’s competitors have higher revenue and earnings than Cerulean Pharma. Cerulean Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

8.1% of Cerulean Pharma shares are held by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 28.6% of Cerulean Pharma shares are held by company insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Cerulean Pharma has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500. Comparatively, Cerulean Pharma’s competitors have a beta of 8.56, suggesting that their average share price is 756% more volatile than the S&P 500.


This table compares Cerulean Pharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cerulean Pharma N/A -228.18% -126.97%
Cerulean Pharma Competitors -5,315.59% -218.31% -39.92%


Cerulean Pharma competitors beat Cerulean Pharma on 8 of the 10 factors compared.

About Cerulean Pharma

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Receive News & Ratings for Cerulean Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma and related companies with MarketBeat.com's FREE daily email newsletter.